5-HT radioligands for human brain imaging with PET and SPECT
Research output: Contribution to journal › Review › Research › peer-review
Standard
5-HT radioligands for human brain imaging with PET and SPECT. / Paterson, Louise M; Kornum, Birgitte R; Nutt, David J; Pike, Victor W; Knudsen, Gitte M.
In: Medicinal Research Reviews, Vol. 33, No. 1, 01.2013, p. 54-111.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - 5-HT radioligands for human brain imaging with PET and SPECT
AU - Paterson, Louise M
AU - Kornum, Birgitte R
AU - Nutt, David J
AU - Pike, Victor W
AU - Knudsen, Gitte M
N1 - © 2011 Wiley Periodicals, Inc.
PY - 2013/1
Y1 - 2013/1
N2 - The serotonergic system plays a key modulatory role in the brain and is the target for many drug treatments for brain disorders either through reuptake blockade or via interactions at the 14 subtypes of 5-HT receptors. This review provides the history and current status of radioligands used for positron emission tomography (PET) and single photon emission computerized tomography (SPECT) imaging of human brain serotonin (5-HT) receptors, the 5-HT transporter (SERT), and 5-HT synthesis rate. Currently available radioligands for in vivo brain imaging of the 5-HT system in humans include antagonists for the 5-HT(1A), 5-HT(1B), 5-HT(2A), and 5-HT(4) receptors, and for SERT. Here we describe the evolution of these radioligands, along with the attempts made to develop radioligands for additional serotonergic targets. We describe the properties needed for a radioligand to become successful and the main caveats. The success of a PET or SPECT radioligand can ultimately be assessed by its frequency of use, its utility in humans, and the number of research sites using it relative to its invention date, and so these aspects are also covered. In conclusion, the development of PET and SPECT radioligands to image serotonergic targets is of high interest, and successful evaluation in humans is leading to invaluable insight into normal and abnormal brain function, emphasizing the need for continued development of both SPECT and PET radioligands for human brain imaging.
AB - The serotonergic system plays a key modulatory role in the brain and is the target for many drug treatments for brain disorders either through reuptake blockade or via interactions at the 14 subtypes of 5-HT receptors. This review provides the history and current status of radioligands used for positron emission tomography (PET) and single photon emission computerized tomography (SPECT) imaging of human brain serotonin (5-HT) receptors, the 5-HT transporter (SERT), and 5-HT synthesis rate. Currently available radioligands for in vivo brain imaging of the 5-HT system in humans include antagonists for the 5-HT(1A), 5-HT(1B), 5-HT(2A), and 5-HT(4) receptors, and for SERT. Here we describe the evolution of these radioligands, along with the attempts made to develop radioligands for additional serotonergic targets. We describe the properties needed for a radioligand to become successful and the main caveats. The success of a PET or SPECT radioligand can ultimately be assessed by its frequency of use, its utility in humans, and the number of research sites using it relative to its invention date, and so these aspects are also covered. In conclusion, the development of PET and SPECT radioligands to image serotonergic targets is of high interest, and successful evaluation in humans is leading to invaluable insight into normal and abnormal brain function, emphasizing the need for continued development of both SPECT and PET radioligands for human brain imaging.
KW - Brain/diagnostic imaging
KW - Humans
KW - Positron-Emission Tomography/methods
KW - Radiopharmaceuticals/metabolism
KW - Receptors, Serotonin/metabolism
KW - Serotonin/chemistry
KW - Serotonin Antagonists/metabolism
KW - Serotonin Plasma Membrane Transport Proteins/metabolism
KW - Tomography, Emission-Computed, Single-Photon/methods
U2 - 10.1002/med.20245
DO - 10.1002/med.20245
M3 - Review
C2 - 21674551
VL - 33
SP - 54
EP - 111
JO - Medicinal Research Reviews
JF - Medicinal Research Reviews
SN - 0198-6325
IS - 1
ER -
ID: 196168856